文献速递妇科肿瘤

低覆盖度全基因组检测卵巢癌同源重组缺陷的临床评估

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
PubMed 文献 · Eur J Cancer · 2024-03-02

研究基于PAOLA-1试验368例患者肿瘤样本,回顾性验证分散式SeqOne检测(浅层全基因组测序联合靶向测序)与Myriad MyChoice HRD检测的一致性及与无进展生存期的关联。两种检测HRD状态一致率为95%,HRD阳性患者中奥拉帕利联合贝伐珠单抗维持治疗的PFS风险比在SeqOne为0.38、Myriad为0.32。

要点

  • SeqOne检测与Myriad MyChoice HRD检测的HRD状态一致率为95%(95%CI 92%-97%)。
  • HRD阳性患者中奥拉帕利联合贝伐珠单抗维持治疗的PFS HR:SeqOne 0.38(95%CI 0.26-0.54),Myriad 0.32(95%CI 0.22-0.45)。
  • BRCA野生型HRD阳性患者中,SeqOne和Myriad检测的PFS HR分别为0.48(95%CI 0.29-0.79)和0.38(95%CI 0.23-0.63)。

核心结论

  • SeqOne检测提供了一种经临床验证的HRD检测方法。

研究设计与样本

  • 研究为回顾性验证,纳入PAOLA-1试验的368例患者肿瘤样本。
  • SeqOne检测基于浅层全基因组测序(sWGS)捕获基因组不稳定性,并结合靶向测序确定BRCA状态,与Myriad MyChoice HRD检测(Myriad Genetics)进行比较,结果按无进展生存期(PFS)分析。

主要发现

  • 两种检测的HRD状态一致率为95%(95%CI 92%-97%)。
  • sWGS检测的阳性百分比 agreement(PPA)为95%(95%CI 91%-97%),阴性百分比 agreement(NPA)为95%(95%CI 89%-98%)。
  • HRD阳性肿瘤患者接受奥拉帕利联合贝伐珠单抗治疗,PFS风险比(HR)在SeqOne检测为0.38(95%CI 0.26-0.54),在Myriad检测为0.32(95%CI 0.22-0.45)。
  • HRD阴性肿瘤患者中,HR在SeqOne检测为0.99(95%CI 0.68-1.42),在Myriad检测为1.05(95%CI 0.70-1.57)。
  • BRCA野生型肿瘤患者中,HRD阳性者从奥拉帕利联合贝伐珠单抗维持治疗中获益,HR在SeqOne检测为0.48(95%CI 0.29-0.79),在Myriad检测为0.38(95%CI 0.23-0.63)。

关键数值与推荐

  • SeqOne检测与Myriad MyChoice HRD检测的HRD状态一致率为95%(95%CI 92%-97%)。
  • SeqOne检测的PPA为95%(95%CI 91%-97%),NPA为95%(95%CI 89%-98%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, the decentralized SeqOne assay, which relies on shallow Whole Genome Sequencing (sWGS) to capture genomic instability and targeted sequencing to determine BRCA status. METHODS: The study comprised 368 patients from the PAOLA-1 trial. The SeqOne assay was compared to the Myriad MyChoice HRD test (Myriad Genetics), and results were analyzed with respect to Progression-Free Survival (PFS). RESULTS: We found a 95% concordance between the HRD status of the two tests (95% Confidence Interval (CI); 92%-97%). The Positive Percentage Agreement (PPA) of the sWGS test was 95% (95% CI; 91%-97%) like its Negative Percentage Agreement (NPA) (95% CI; 89%-98%). In patients with HRD-positive tumors treated with olaparib plus bevacizumab, the PFS Hazard Ratio (HR) was 0.38 (95% CI; 0.26-0.54) with SeqOne assay and 0.32 (95% CI; 0.22-0.45) with the Myriad assay. In patients with HRD-negative tumors, HR was 0.99 (95% CI; 0.68-1.42) and 1.05 (95% CI; 0.70-1.57) with SeqOne and Myriad assays. Among patients with BRCA-wildtype tumors, those with HRD-positive tumors, benefited from olaparib plus bevacizumab maintenance, with HR of 0.48 (95% CI: 0.29-0.79) and of 0.38 (95% CI: 0.23 to 0.63) with the SeqOne and Myriad assay. CONCLUSION: The SeqOne assay offers a clinically validated approach to detect HRD.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Boidot R, Blum MGB, Wissler MP, et al. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer. Eur J Cancer. 2024. PMID: 38471290. doi:10.1016/j.ejca.2024.113978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。